CapsoVision, Inc CV
Biotechnology: Electromedical & Electrotherapeutic Apparatus · IPO 2025 · data as of November 13, 2026
CapsoVision, Inc (CV) is a healthcare company listed in the US with a market value of about $323M. In the twelve months to September 30, 2026 it had revenue of $14M and net income of -$29M, a net margin of -210.1%.
Its overall Stock Analiz score is 0.8 out of 5 (weak). The strongest part is future growth (2/5); the weakest is value (0/5).
Key numbers: a 5-year average ROIC of -142%.
About CapsoVision
CapsoVision is listed in the US and classified in biotechnology: electromedical & electrotherapeutic apparatus, IPO year 2025. It was profitable in 0 of the last 2 years in our data. It spends 135% of revenue on research and development.
Score: 0.8 / 5
Checks passed
- Revenue growth above 10% last year
- Strong R&D investment or growth above 20%
- More cash than debt, or low debt to equity
- Liabilities below 60% of assets
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- 3-year revenue growth above 10% a year
- Profit margin improving
- 3-year free cash flow growth above 10% a year
Valuation
Growth and quality
Financials, last 2 years
| Fiscal year | TTM | 2025 | 2024 |
|---|---|---|---|
| Revenue | $14M | $14M | $12M |
| Net income | -$29M | -$25M | -$20M |
| Free cash flow | -$29M | -$23M | -$20M |
| EPS (diluted) | $-0.43 | $-1.03 | $-9.85 |
| Net margin | -210.1% | -186.8% | -169.3% |
| ROIC | — | -142.5% | — |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 2 analysts is $9.50, 58% above the current price; targets range from $9.00 to $10.00; the consensus rating is “Strong buy”; expected EPS is $-0.56 for the fiscal year ending December 31, 2026.
Frequently asked questions
Does CapsoVision pay a dividend?
Not currently.
Is CapsoVision a good stock to buy?
We do not give buy or sell advice. CapsoVision scores 0.8 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.